Using Ketamine Troches for Maintenance vs. Acute Treatment

Ketamine troches for maintenance vs acute treatment follow different schedules, doses, and goals, even though the medication and delivery method stay the same. Acute treatment (the loading phase) uses a higher frequency of sessions over several weeks to produce a meaningful reduction in depression, anxiety, or pain symptoms. Maintenance treatment follows once that response is established, using fewer sessions and often lower doses to sustain the improvement and prevent relapse. This guide walks through both phases: how loading protocols work, when to transition to maintenance, how long maintenance typically lasts, and how to tell appropriate long-term treatment apart from a developing dependency.

Acute Treatment vs. Maintenance: Different Goals

Ketamine therapy for depression, anxiety, and chronic pain typically unfolds in two phases that call for different protocols, dosing, and expectations. For a full overview of how troches work before comparing these phases, see our sublingual ketamine therapy guide.

Acute treatment (also called the loading phase or induction phase) aims to rapidly achieve a therapeutic effect, producing a meaningful reduction in symptoms within days to weeks. Maintenance treatment aims to sustain the benefit achieved during the acute phase, preventing relapse and protecting the functional gains made. Troches can serve both purposes, but frequency, dosing, and expectations differ substantially between them.

The Acute Treatment Phase With Troches

Standard Loading Protocols

Most ketamine troche prescribers use one of several loading protocols to achieve an initial antidepressant or analgesic effect. For more detail on how dose timing and spacing works within a week, see our guide to troche onset, peak, and duration.

• Twice-weekly protocol: Sessions on two non-consecutive days per week (for example, Monday and Thursday) for 4 to 6 weeks. This mirrors the structure of IV ketamine acute treatment protocols adapted for the outpatient sublingual setting.
• Three-times-weekly protocol: Used for patients with severe symptoms or an incomplete response to twice-weekly dosing. This more intensive protocol typically runs 2 to 4 weeks before reassessment.
• Weekly protocol: Used when patients can tolerate a slower course, have logistical constraints, or when clinical judgment supports a less intensive approach. Response may take longer to establish, but the protocol is more sustainable.

What to Expect During Acute Treatment

During the loading phase, most patients experience a gradual but meaningful improvement in their primary symptoms:

• For depression: reduced hopelessness, improved energy, decreased ruminative thinking, improved sleep
• For anxiety: reduced worry and physiological arousal, increased willingness to engage with previously avoided situations
• For chronic pain: reduced pain intensity and improved function

Full response typically emerges after 3 to 6 weeks of consistent treatment, though some patients notice improvement after the first or second session. A partial response by 4 to 6 weeks is a signal to reassess dose, frequency, and whether additional support, such as concurrent psychotherapy or a medication adjustment, is needed.

Dose Range for Acute Treatment

Acute treatment doses sit in the moderate to higher range of the prescribed spectrum, set through individual titration. Common acute treatment doses range from 150 to 400 mg per session, with the exact dose established by working with the prescriber to find the level that produces effect without excessive side effects.

Transitioning to Maintenance

Once a patient has achieved an adequate response during the acute phase, meaningful symptom reduction (typically a 50 percent or greater improvement on clinical rating scales) that persists between sessions, the focus shifts to maintaining that improvement.

When to Transition

Indicators that a patient is ready to move from acute to maintenance treatment include:

• Sustained improvement lasting 5 to 7 days or longer between sessions
• Reduced symptom burden that allows a return to valued activities
• Patient and provider agreement that the acute phase goals have been met
• Stable social and functional status

The transition is gradual. Session frequency is reduced incrementally rather than stopped abruptly.

Standard Maintenance Protocols

• Weekly maintenance: The first step down from twice-weekly or three-times-weekly acute treatment. Weekly sessions help maintain the neurobiological changes associated with ketamine's effect, including sustained BDNF (brain-derived neurotrophic factor) signaling and synaptic remodeling, without the intensity of a loading schedule. According to StatPearls' clinical reference on ketamine, these neuroplastic changes are part of the proposed mechanism behind ketamine's rapid antidepressant effect.
• Biweekly maintenance (every 2 weeks): The most common long-term maintenance frequency for patients who have been in remission for 3 or more months. Most patients in stable remission can sustain their improvement on biweekly sessions.
• Monthly maintenance: For patients who show durable responses lasting 3 to 4 weeks between sessions. Monthly maintenance is more cost-effective and limits cumulative dose exposure over time.
• As-needed maintenance: Some long-term patients learn to recognize early warning signs of relapse (sleep deterioration, returning rumination, increasing pain) and use a single troche session in response. This approach is less structured and tends to suit motivated, experienced patients who have been stable for extended periods.

Maintenance Dose

Maintenance doses are often lower than acute treatment doses, sometimes by 25 to 50 percent. After the neuroplasticity "priming" effect of the acute phase, smaller doses are often sufficient to maintain the therapeutic signal. Many providers deliberately keep maintenance doses conservative to limit cumulative exposure and reduce the risk of adverse effects or tolerance.

How Long Does Maintenance Last?

This is one of the most common questions patients ask, and the honest answer is that it depends on the individual:

• Short-term maintenance: Some patients with situational depression or a single episode reach lasting remission after a 3 to 6 month course and successfully stop ketamine treatment.
• Long-term maintenance: Patients with chronic treatment-resistant depression, chronic pain, or a recurring condition may need indefinite maintenance to prevent relapse. The National Institute of Mental Health notes that treatment-resistant depression, depression that does not improve after trying at least two antidepressants, often requires a longer-term, multi-modal treatment approach.
• Time-limited trials off ketamine: Most providers recommend periodic trials of a lower frequency or full cessation, with close monitoring, to assess whether ketamine is still needed.

For most patients, the trajectory is a gradual reduction in frequency over 6 to 18 months if they remain stable, with reinduction if relapse occurs.

Response Durability: What Determines How Long Benefit Lasts

According to the World Health Organization, depression affects more than 280 million people worldwide, and a meaningful share of those cases do not respond fully to standard antidepressants, which is part of why maintenance protocols matter for the subset of patients using ketamine. Not all patients maintain improvement equally well between sessions. Several factors affect response durability:

• Concurrent antidepressant therapy: Patients maintained on oral antidepressants during ketamine treatment often show longer-lasting responses than those on ketamine alone. The antidepressant may help sustain the neuroplastic changes that ketamine initiates.
• Psychotherapy: Integration therapy and ongoing psychotherapy are associated with more durable ketamine responses. Without psychological work to consolidate insights and behavior changes, the neurobiological window opened by ketamine may not be fully used.
• Lifestyle factors: Sleep quality, physical activity, and social connection all influence response durability. Patients who make lifestyle changes during ketamine treatment tend to maintain responses longer.
• Underlying diagnosis: Treatment-resistant depression linked to specific biological factors, such as elevated inflammatory markers or genetic vulnerabilities, may relapse more quickly than depression with clearer psychosocial triggers. See our guide on treatment-resistant depression and troche options for more on this population.

Tapering and Discontinuation

When transitioning off ketamine, whether after a stable period or by mutual decision with the provider, the process should be gradual:

• Reduce session frequency progressively, not all at once
• Monitor symptom scores closely during each frequency reduction
• Have a clear plan for reinduction if symptoms return
• Continue psychotherapy and other supportive treatments during the taper

For data on how often patients stop treatment and why, see our analysis of discontinuation rates by delivery format.

Distinguishing Response from Dependency

Patients and providers need to tell the difference between maintaining a medically necessary treatment that prevents relapse and a psychological or pharmacological dependency that needs its own intervention. Ongoing, honest communication with your provider is the best protection against inappropriate use patterns developing. Our ketamine troche safety guide covers monitoring practices in more detail.